Effectiveness and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A protocol for Systematic review and Meta-analysis

BACKGROUND: Type 1 Diabetes Mellitus (T1DM) has long required insulin treatment. Sotagliflflozin (SOTA), as a dual SGLT-1/2 inhibitor, has the potential to be the first oral antidiabetic drug (OAD) to be approved for T1DM in the US market. It is important to evaluate the effectiveness of SOTA for T1...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mao-Bing, Xu, Rui-Jun, Zheng, Qi-Han, Zheng, Xu-Wen, Wang, Hua, Ding, Yun-Long, Yue, Mao-Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831156/
https://www.ncbi.nlm.nih.gov/pubmed/31415414
http://dx.doi.org/10.1097/MD.0000000000016850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831156/
https://www.ncbi.nlm.nih.gov/pubmed/31415414
http://dx.doi.org/10.1097/MD.0000000000016850

Ejemplares similares